Frequency of Serious Adverse Skin Reactions Caused by Continuous Subcutaneous Administration of Psychotropic Drugs
10.2512/jspm.11.123
- VernacularTitle:向精神薬の持続皮下投与における重篤な皮膚有害事象の発生頻度の検討
- Author:
Ritsuko Yabuki
;
Takayuki Hisanaga
;
Daisuke Kiuchi
;
Miho Shimokawa
;
Katsuya Abe
;
Takahiro Otsuka
;
Ayako Sakurai
;
Satoko Suda
;
Yasuo Shima
- Publication Type:Journal Article
- Keywords:
continuous subcutaneous administration;
adverce skin reactions;
chlorpromazine;
levomepromazine;
midazolam
- From:Palliative Care Research
2016;11(1):123-127
- CountryJapan
- Language:Japanese
-
Abstract:
Continuous subcutaneous injections of medication are effective in controlling symptoms of the terminal stage of cancer. Chlorpromazine and levomepromazine occasionally cause skin irritation. We examined all patients who underwent continuous subcutaneous administration of psychotropic drugs (chlorpromazine, levomepromazine, midazolam) at the palliative care unit of our hospital from April 2010 to March 2013, the frequency of adverse skin reactions of Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 3 or above. Of the 603 hospitalized patients, 389 (64.5%) underwent continuous subcutaneous administration of one of the three drugs. The frequency of grade 3 or above (ulceration or necrosis) adverse skin reactions was 4 out of 345 chlorpromazine cases (1.2%; 95% CI: 0.0-2.3%), 2 out of 90 levomepromazine cases (2.2%; 95% CI: −0.8-5.2%), and 0 out of 210 midazolam cases (0.0%; 95% CI: 0.0-0.0%). The frequency of serious adverse skin reactions caused by continuous subcutaneous administration of psychotropic drugs was low, suggesting that this treatment is relatively safe for the skin.
